Financhill
Sell
14

NRC Quote, Financials, Valuation and Earnings

Last price:
$17.16
Seasonality move :
-3.7%
Day range:
$16.82 - $17.88
52-week range:
$16.74 - $42.18
Dividend yield:
2.8%
P/E ratio:
15.19x
P/S ratio:
2.86x
P/B ratio:
11.64x
Volume:
333.3K
Avg. volume:
104.7K
1-year change:
-56.56%
Market cap:
$403.1M
Revenue:
$148.6M
EPS (TTM):
$1.13

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NRC
National Research
-- -- -- -- --
DRIO
DarioHealth
$7.4M -$0.18 104.95% -60.98% --
FOXO
FOXO Technologies
-- -- -- -- --
OTRK
Ontrak
$2.6M -- -13% -- --
SPOK
Spok Holdings
$34.3M $0.24 4.56% 18.18% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NRC
National Research
$17.17 -- $403.1M 15.19x $0.12 2.8% 2.86x
DRIO
DarioHealth
$0.80 -- $27.3M -- $0.00 0% 1.25x
FOXO
FOXO Technologies
$0.28 -- $4.9M -- $0.00 0% 2.10x
OTRK
Ontrak
$1.44 -- $6.1M -- $0.00 0% 0.50x
SPOK
Spok Holdings
$15.96 -- $323.5M 21.86x $0.31 7.83% 2.37x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NRC
National Research
60.77% 1.215 10.52% 0.34x
DRIO
DarioHealth
33.03% 1.132 82.25% 1.27x
FOXO
FOXO Technologies
224.55% 16.543 1241.69% 0.06x
OTRK
Ontrak
40.88% 4.227 95.85% 0.98x
SPOK
Spok Holdings
-- 0.265 -- 1.08x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NRC
National Research
$20.5M $8M 32.47% 61.94% 22.34% $7.8M
DRIO
DarioHealth
$3.9M -$12M -49.97% -71.65% -162.06% -$7.4M
FOXO
FOXO Technologies
$655K -$1.1M -- -- -83.28% $576K
OTRK
Ontrak
$1.6M -$5.1M -149.3% -231.34% -198.72% -$1.4M
SPOK
Spok Holdings
$27.7M $5.3M 9.13% 9.13% 15.31% $10.3M

National Research vs. Competitors

  • Which has Higher Returns NRC or DRIO?

    DarioHealth has a net margin of 15.88% compared to National Research's net margin of -166.11%. National Research's return on equity of 61.94% beat DarioHealth's return on equity of -71.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    NRC
    National Research
    57.27% $0.24 $88.3M
    DRIO
    DarioHealth
    52.23% -$0.25 $87.4M
  • What do Analysts Say About NRC or DRIO?

    National Research has a consensus price target of --, signalling downside risk potential of --. On the other hand DarioHealth has an analysts' consensus of -- which suggests that it could grow by 337.5%. Given that DarioHealth has higher upside potential than National Research, analysts believe DarioHealth is more attractive than National Research.

    Company Buy Ratings Hold Ratings Sell Ratings
    NRC
    National Research
    0 0 0
    DRIO
    DarioHealth
    3 0 0
  • Is NRC or DRIO More Risky?

    National Research has a beta of 0.516, which suggesting that the stock is 48.38% less volatile than S&P 500. In comparison DarioHealth has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.822%.

  • Which is a Better Dividend Stock NRC or DRIO?

    National Research has a quarterly dividend of $0.12 per share corresponding to a yield of 2.8%. DarioHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research pays 117.42% of its earnings as a dividend. DarioHealth pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NRC or DRIO?

    National Research quarterly revenues are $35.8M, which are larger than DarioHealth quarterly revenues of $7.4M. National Research's net income of $5.7M is higher than DarioHealth's net income of -$12.3M. Notably, National Research's price-to-earnings ratio is 15.19x while DarioHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research is 2.86x versus 1.25x for DarioHealth. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NRC
    National Research
    2.86x 15.19x $35.8M $5.7M
    DRIO
    DarioHealth
    1.25x -- $7.4M -$12.3M
  • Which has Higher Returns NRC or FOXO?

    FOXO Technologies has a net margin of 15.88% compared to National Research's net margin of -162.71%. National Research's return on equity of 61.94% beat FOXO Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NRC
    National Research
    57.27% $0.24 $88.3M
    FOXO
    FOXO Technologies
    54.77% -$0.15 $14M
  • What do Analysts Say About NRC or FOXO?

    National Research has a consensus price target of --, signalling downside risk potential of --. On the other hand FOXO Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that National Research has higher upside potential than FOXO Technologies, analysts believe National Research is more attractive than FOXO Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NRC
    National Research
    0 0 0
    FOXO
    FOXO Technologies
    0 0 0
  • Is NRC or FOXO More Risky?

    National Research has a beta of 0.516, which suggesting that the stock is 48.38% less volatile than S&P 500. In comparison FOXO Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock NRC or FOXO?

    National Research has a quarterly dividend of $0.12 per share corresponding to a yield of 2.8%. FOXO Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research pays 117.42% of its earnings as a dividend. FOXO Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NRC or FOXO?

    National Research quarterly revenues are $35.8M, which are larger than FOXO Technologies quarterly revenues of $1.2M. National Research's net income of $5.7M is higher than FOXO Technologies's net income of -$1.9M. Notably, National Research's price-to-earnings ratio is 15.19x while FOXO Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research is 2.86x versus 2.10x for FOXO Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NRC
    National Research
    2.86x 15.19x $35.8M $5.7M
    FOXO
    FOXO Technologies
    2.10x -- $1.2M -$1.9M
  • Which has Higher Returns NRC or OTRK?

    Ontrak has a net margin of 15.88% compared to National Research's net margin of -217.21%. National Research's return on equity of 61.94% beat Ontrak's return on equity of -231.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    NRC
    National Research
    57.27% $0.24 $88.3M
    OTRK
    Ontrak
    62.05% -$1.77 $19.4M
  • What do Analysts Say About NRC or OTRK?

    National Research has a consensus price target of --, signalling downside risk potential of --. On the other hand Ontrak has an analysts' consensus of -- which suggests that it could grow by 177.78%. Given that Ontrak has higher upside potential than National Research, analysts believe Ontrak is more attractive than National Research.

    Company Buy Ratings Hold Ratings Sell Ratings
    NRC
    National Research
    0 0 0
    OTRK
    Ontrak
    0 0 0
  • Is NRC or OTRK More Risky?

    National Research has a beta of 0.516, which suggesting that the stock is 48.38% less volatile than S&P 500. In comparison Ontrak has a beta of 2.569, suggesting its more volatile than the S&P 500 by 156.857%.

  • Which is a Better Dividend Stock NRC or OTRK?

    National Research has a quarterly dividend of $0.12 per share corresponding to a yield of 2.8%. Ontrak offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. National Research pays 117.42% of its earnings as a dividend. Ontrak pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NRC or OTRK?

    National Research quarterly revenues are $35.8M, which are larger than Ontrak quarterly revenues of $2.6M. National Research's net income of $5.7M is higher than Ontrak's net income of -$5.6M. Notably, National Research's price-to-earnings ratio is 15.19x while Ontrak's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research is 2.86x versus 0.50x for Ontrak. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NRC
    National Research
    2.86x 15.19x $35.8M $5.7M
    OTRK
    Ontrak
    0.50x -- $2.6M -$5.6M
  • Which has Higher Returns NRC or SPOK?

    Spok Holdings has a net margin of 15.88% compared to National Research's net margin of 10.5%. National Research's return on equity of 61.94% beat Spok Holdings's return on equity of 9.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    NRC
    National Research
    57.27% $0.24 $88.3M
    SPOK
    Spok Holdings
    79.54% $0.18 $156.3M
  • What do Analysts Say About NRC or SPOK?

    National Research has a consensus price target of --, signalling downside risk potential of --. On the other hand Spok Holdings has an analysts' consensus of -- which suggests that it could fall by -6.02%. Given that Spok Holdings has higher upside potential than National Research, analysts believe Spok Holdings is more attractive than National Research.

    Company Buy Ratings Hold Ratings Sell Ratings
    NRC
    National Research
    0 0 0
    SPOK
    Spok Holdings
    0 0 0
  • Is NRC or SPOK More Risky?

    National Research has a beta of 0.516, which suggesting that the stock is 48.38% less volatile than S&P 500. In comparison Spok Holdings has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.63%.

  • Which is a Better Dividend Stock NRC or SPOK?

    National Research has a quarterly dividend of $0.12 per share corresponding to a yield of 2.8%. Spok Holdings offers a yield of 7.83% to investors and pays a quarterly dividend of $0.31 per share. National Research pays 117.42% of its earnings as a dividend. Spok Holdings pays out 163.68% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios NRC or SPOK?

    National Research quarterly revenues are $35.8M, which are larger than Spok Holdings quarterly revenues of $34.9M. National Research's net income of $5.7M is higher than Spok Holdings's net income of $3.7M. Notably, National Research's price-to-earnings ratio is 15.19x while Spok Holdings's PE ratio is 21.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for National Research is 2.86x versus 2.37x for Spok Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NRC
    National Research
    2.86x 15.19x $35.8M $5.7M
    SPOK
    Spok Holdings
    2.37x 21.86x $34.9M $3.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock